Roche presented additional Phase III data for fenebrutinib, its investigational oral Bruton tyrosine kinase inhibitor, at MSToronto2026.
Across the FENhance and FENtrepid programs, Roche reported reductions of up to 30% in slowly expanding lesion volume and a 62% reduction in accumulation of paramagnetic rim lesions in relapsing multiple sclerosis, compared with active comparators.
Pooled FENhance data also showed a 23% reduction in annual brain-volume loss and a 16% reduction in 12-week composite confirmed disability progression.
The company reiterated a 55% reduction in annualized relapse rate versus teriflunomide; importantly, the principal relapse-efficacy results had already been disclosed earlier in 2026. Roche
Primary source: Roche — MSToronto2026 Phase III data, October 21
Why it matters strategically
The new findings are relevant because multiple sclerosis treatment increasingly focuses on preventing long-term disability rather than controlling acute relapses alone.
Fenebrutinib is intended to act on inflammatory mechanisms in both the peripheral immune system and central nervous system.
The reduction in chronic active lesions provides additional evidence that the drug affects disease processes associated with progressive neurological injury.
However, three outcomes must be distinguished.
Inflammatory disease control: Reduction in relapses and active MRI lesions.
Structural disease modification: Reduction in chronic lesion expansion and brain-volume loss.
Clinical disability prevention: Preservation of mobility, upper-limb function, cognition, and independence.
These outcomes are related but not interchangeable.
